GET THE APP

Renal Cell Carcinoma: Diagnostic and Immunotherapeutic Value of CD248 | Abstract
Scholars Research Library

Scholars Research Library

A-Z Journals

+44 7389645282

Annals of Experimental Biology

Abstract

Renal Cell Carcinoma: Diagnostic and Immunotherapeutic Value of CD248

Author(s): Alice Brown*

The most frequent kind of cancer in the urinary system is Renal Cell Carcinoma (RCC). The survival outcome for advanced RCC remains unsatisfactory despite notable advancements in therapy. Finding novel biomarkers to help with early diagnosis and screen patients for immunotherapy sensitivity would be advantageous. A promising possibility that needs to be looked at is CD248. The dataset from the Cancer Genome Atlas (TCGA) and a clinical sample were used to compare the expression of CD248 in normal and malignant tissues. A CD248-based prognostic signature was created using univariate and multivariate Cox regression analysis to find independent predictive variables. The relationship between the current signature, immune cells that have infiltrated the tumor, the Tumor Mutation Burden (TMB), and immunomodulatory chemicals were assessed. To investigate the underlying mechanism of CD248 in RCC progression, Weighted Gene Coexpression Network Analysis (WGCNA) and enrichment analysis were carried out. A useful biomarker to boost RCC diagnosis and treatment effectiveness is CD248. Co-expressed CD248 genes' immunosuppressive effects could shed light on the current investigation.